Intercell Jumps on Sale to France’s Vivalis

Intercell AG rose the most since January after the Austrian vaccine maker agreed to sell itself to Vivalis SA of France for about 124.5 million euros ($164 million) following setbacks in clinical trials.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.